Akorn, Inc. (OTCMKTS: AKRXQ) is a specialty pharmaceutical company focused on the development, manufacturing and marketing of branded and generic prescription pharmaceuticals, generic injectable products, ophthalmics and intradermal tests. Headquartered in Lake Forest, Illinois, Akorn operates manufacturing facilities in the United States that support its acute care, consumer health and ophthalmic business segments. The company’s product portfolio spans sterile injectables, ophthalmic solutions, dermatology treatments and intradermal allergy tests, catering to hospitals, clinics, and specialty pharmacies nationwide.
Within its acute care division, Akorn provides a range of high-quality sterile injectables including antibiotics, analgesics and critical care therapies. Its ophthalmic segment offers eye care products such as anti-inflammatory drops, antibiotics and ocular lubricants. The dermatology group markets topical treatments for conditions like eczema and psoriasis, while the consumer health unit delivers over-the-counter intradermal allergy testing solutions under well-known brands. Akorn’s integrated supply chain and in-house R&D capabilities allow the company to support customers with reliable product availability and responsive development timelines.
Founded in 1971, Akorn built its reputation on quality manufacturing and technical expertise in sterile formulations. Over the decades, the company has expanded through a combination of organic growth and strategic acquisitions, enhancing its capabilities in both branded specialty pharmaceuticals and complex generics. Today, Akorn serves a broad U.S. footprint and maintains partnerships with contract wholesalers, hospital group purchasing organizations and specialty distributors to reach patients and healthcare providers.
Akorn is led by an experienced management team with deep roots in the pharmaceutical industry. The company’s leadership emphasizes regulatory compliance, robust manufacturing standards and continuous process improvement to ensure patient safety and product reliability. With a commitment to innovation and operational excellence, Akorn continues to advance its pipeline of generic injectable and ophthalmic candidates while supporting its established product lines.
AI Generated. May Contain Errors.
